English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduHigh-dose anticoagulation can reduce deaths by 30 percent and intubations by 25 percent in hospitalized COVID-19 patients who are not critically ill when compared to the standard treatment, which is low-dose anticoagulation.
Tag: covid 19 trials
New Research Supports Sofosbuvir in Combination with Other Antivirals for COVID-19
Columbia Engineering researchers report that Sofosbuvir-terminated RNA is more resistant to the proofreader of SARS-CoV-2, the virus that causes COVID-19, than Remdesivir-terminated RNA. The results of the new study, published today by the Nature Research journal Scientific Reports, support the use of the FDA-approved hepatitis C drug EPCLUSA—Sofosbuvir/Velpatasvir—in combination with other drugs in COVID-19 clinical trials.
Baylor Scott & White Health Enrolls First Patients in the World in Trial for Inhaled Remdesivir
Earlier this month, Baylor Scott & White Research Institute enrolled the first four patients in the world on Gilead’s new clinical trial involving an investigational inhaled solution of remdesivir (NCT04539262). This is Gilead’s first trial in COVID-19 patients examining the safety and efficacy of an inhaled solution of the drug in an outpatient setting. The study of an inhaled solution asks whether this mode of delivery can help reduce the amount of virus from the airways earlier.
Participants Sought for National Trial of COVID-19 Vaccine
Rush University Medical Center is recruiting participants for a nationwide trial of a COVID-19 vaccine developed by the University of Oxford in England and AstraZeneca, a multinational pharmaceutical company.
Baylor Scott & White Research Institute Expands Efforts in the Fight Against COVID-19
As the global response to the SARS-COV-2 virus that causes COVID-19 approaches 200 days, Baylor Scott & White Research Institute, the research and development arm of Baylor Scott & White Health, is accelerating its pace of bringing clinical trials online.
Baylor Scott & White Research Institute continues to mobilize staff and resources, including components needed to integrate critical patient-safety measures at every participating site within the Baylor Scott & White system for industry sponsored drug trials, investigator-initiated drug trials and research studies, and observational and data studies designed to help increase knowledge around case trends, viral epidemiology, and care best practices.
Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense Funding
Mount Sinai and Emergent to conduct clinical trials to evaluate COVID-HIG for post-exposure prophylaxis of COVID-19 in front-line health care workers and to support a potential Expanded Access Program for military personnel with funding from the U.S. Department of Defense
– ImmunoTek to extend operating license and provide training to Mount Sinai to establish onsite plasma collection to support production of COVID-HIG
Health Care Workers at Rush Invited to Participate in National PCORnet Study of Hydroxychloroquine for COVID-19 Preventio
Rush University Medical Center has opened enrollment for a new clinical trial investigating whether the drug hydroxychloroquine is better than a placebo in preventing COVID-19 infection in healthy people working in health care settings.
Jersey Shore University Medical Center Treating COVID-19 Patients with Convalescent Plasma
As a leading New Jersey academic medical center and member of Hackensack Meridian Health, Jersey Shore University Medical Center is able to provide its patients access to existing clinical trials and the latest medical techniques in a variety of specialties. Currently, the medical center is recruiting individuals who have been clinically diagnosed with COVID-19 or have laboratory test results showing they have COVID-19 antibodies to donate their blood and potentially assist patients in their recovery from the virus.
Story Tips From Johns Hopkins Experts on Covid-19
It seems as though there will never be enough “thank-you’s” for the incredible doctors, nurses, technicians and support staff who are working around the clock to help patients with this dangerous coronavirus disease. It’s their dedication, determination and spirit that enable Johns Hopkins to deliver the promise of medicine.